SCHEMBL280087

SCHEMBL280087

Cc1cccc(C(=O)N2CC(O)C(O)C2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.64
HTT P42858 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
HSD17B10 Q99714 1/20 0.55
GABRD O14764 1/20 0.52
GABRA1 P14867 1/20 0.52
GABRB1 P18505 1/20 0.52
GABRA5 P31644 1/20 0.52
GABRA3 P34903 1/20 0.52
GABRA2 P47869 1/20 0.52
GABRB2 P47870 1/20 0.52
GABRA4 P48169 1/20 0.52
HSD11B1 P28845 1/20 0.52
MGLL Q99685 1/20 0.52
EPHX2 P34913 1/20 0.50
ENPP3 O14638 1/20 0.49
ALPL P05186 1/20 0.49
XIAP P98170 1/20 0.49
PARP1 P09874 1/20 0.49
KDM4E B2RXH2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2667154 0.90 HPGD (0.64) HPGDHTTL3MBTL1HSD17B10GABRD
SCHEMBL10329768 0.87 HTT (0.65) HPGDHTTL3MBTL1HSD17B10GABRD
SCHEMBL2633022 0.85 HPGD (0.62) HPGDHTTL3MBTL1HSD17B10GABRD
SCHEMBL18377751 0.85 HPGD (0.62) HPGDHTTL3MBTL1HSD17B10GABRD
SCHEMBL279579 0.84 L3MBTL1 (0.62) HPGDHTTL3MBTL1HSD17B10GABRD
SCHEMBL18377898 0.83 HPGD (0.59) HPGDHTTL3MBTL1HSD17B10GABRD
SCHEMBL18377903 0.83 HPGD (0.59) HPGDHTTL3MBTL1HSD17B10GABRD
SCHEMBL7130857 0.82 HPGD (0.83) HPGDHTTL3MBTL1GABRDGABRA1
SCHEMBL14238822 0.82 HPGD (0.83) HPGDHTTL3MBTL1GABRDGABRA1
SCHEMBL22735405 0.81 HTT (0.63) HPGDHTTL3MBTL1GABRDGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL HPGD 1895/4885HTT 1630/4885L3MBTL1 676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.